Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs. -
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related. -
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
UROLOGIC CANCERS NEWS
First-in-Class, Targeted Therapy Approved for Metastatic Bladder Cancer
Bladder Cancer Risk Elevated in Statin Users
The Predictive Ability of a Cancer Subtype Ontology Assignment
High Monocyte-to-Lymphocyte Ratio Predictive of OS in Advanced Gallbladder Cancer
Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
